Details:
KHK7791 (Tenapanor) effect of decreasing pill burden of phosphate binders, which is the outcome of a phase 2 study of tenapanor for hemodialysis patients with hyperphosphatemia in Japan, was presented in a poster session virtually at ERA-EDTA 2020 annual meeting.
Lead Product(s): Tenapanor
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Ardelyx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020